MNK

Mallinckrodt Plc
NYSE

Real-time Quotes | Nasdaq Last Sale

1.435
+0.035
+2.50%
Opening 11:00 08/12 EDT
OPEN
1.440
PREV CLOSE
1.400
HIGH
1.460
LOW
1.400
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
6.42
52 WEEK LOW
1.000
MARKET CAP
121.39M
P/E (TTM)
-0.0558
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNK stock price target is 1.778 with a high estimate of 3.000 and a low estimate of 1.000.

EPS

MNK News

More
FDA accepts Mallinckrodt application for burn treatment StrataGraft
The FDA accepts for review Mallinckrodt's (NYSE:MNK) marketing application seeking approval of StrataGraft, a regenerative skin tissue therapy, for the tre
seekingalpha · 1d ago
Mallinckrodt shares are trading higher after the company announced the FDA has accepted to review the Stratatech Biologics License Application for StrataGraft, a regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns.
Benzinga · 2d ago
Mallinckrodt Announces US FDA Filing Acceptance of Biologics License Application for StrataGraft Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns
Benzinga · 2d ago
Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Stratatech Biologics License Application (BLA) for StrataGraft®, an investigational regenerative skin
PR Newswire · 2d ago
Were Hedge Funds Right About Ditching Mallinckrodt Public Limited Company (MNK)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 6d ago
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Zacks · 6d ago
Mallinckrodt shares are trading lower on continued momentum from yesterday after the company announced its possible that it and most of its subsidiaries could file for Chapter 11 reorganization in the near term.
Benzinga · 08/05 14:19
DOJ wants as much as $18.1B from Purdue Pharma for opioid epidemic
The U.S. Department of Justice is demanding OxyContin maker Purdue Pharma pay as much as $18.1B in penalties as part of its bankruptcy reorganization plan,
seekingalpha · 08/05 12:53

Industry

Pharmaceuticals
+1.98%
Pharmaceuticals & Medical Research
+1.54%

Hot Stocks

Symbol
Price
%Change

About MNK

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
More

Webull offers kinds of Mallinckrodt PLC stock information, including NYSE:MNK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNK stock methods without spending real money on the virtual paper trading platform.